Cargando…
Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting
BACKGROUND: We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage. METHODS: We simulate a dynamic...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150186/ https://www.ncbi.nlm.nih.gov/pubmed/30096067 http://dx.doi.org/10.1097/QAD.0000000000001959 |
_version_ | 1783356938684203008 |
---|---|
author | Rhines, Allison S. Feldman, Marcus W. Bendavid, Eran |
author_facet | Rhines, Allison S. Feldman, Marcus W. Bendavid, Eran |
author_sort | Rhines, Allison S. |
collection | PubMed |
description | BACKGROUND: We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage. METHODS: We simulate a dynamic compartmental model of age-structured HIV and TB coepidemics in South Africa. HIV dynamics are modeled by infection status, CD4(+) cell count, and antiretroviral therapy; TB dynamics are modeled by disease stage, diagnosis, treatment, and IPT status. We analyze the effects of continuous IPT coverage among adolescents from 5 (baseline) to 90%. RESULTS: Our model is calibrated to WHO and the Joint United Nations Programme on HIV/AIDS epidemiological estimates. In simulations, increasing IPT coverage to 50% among adolescents reduced active TB incidence by 5–34%. Increasing coverage to 90% led to a 9–40% reduction in active TB incidence. Expanded IPT access causes TB incidence to decline in the general population of HIV-positive individuals, as well as in adult HIV-positive individuals. CONCLUSION: Targeting IPT to a secondary school population with high latent TB prevalence and low-HIV prevalence, in which risk of false-negative diagnosis of active TB is low and IPT benefits are more established, could have substantial benefits to adolescents and spillover benefits to the adult population. |
format | Online Article Text |
id | pubmed-6150186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-61501862018-10-12 Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting Rhines, Allison S. Feldman, Marcus W. Bendavid, Eran AIDS Basic Science BACKGROUND: We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage. METHODS: We simulate a dynamic compartmental model of age-structured HIV and TB coepidemics in South Africa. HIV dynamics are modeled by infection status, CD4(+) cell count, and antiretroviral therapy; TB dynamics are modeled by disease stage, diagnosis, treatment, and IPT status. We analyze the effects of continuous IPT coverage among adolescents from 5 (baseline) to 90%. RESULTS: Our model is calibrated to WHO and the Joint United Nations Programme on HIV/AIDS epidemiological estimates. In simulations, increasing IPT coverage to 50% among adolescents reduced active TB incidence by 5–34%. Increasing coverage to 90% led to a 9–40% reduction in active TB incidence. Expanded IPT access causes TB incidence to decline in the general population of HIV-positive individuals, as well as in adult HIV-positive individuals. CONCLUSION: Targeting IPT to a secondary school population with high latent TB prevalence and low-HIV prevalence, in which risk of false-negative diagnosis of active TB is low and IPT benefits are more established, could have substantial benefits to adolescents and spillover benefits to the adult population. Lippincott Williams & Wilkins 2018-09-24 2018-09-19 /pmc/articles/PMC6150186/ /pubmed/30096067 http://dx.doi.org/10.1097/QAD.0000000000001959 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Basic Science Rhines, Allison S. Feldman, Marcus W. Bendavid, Eran Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting |
title | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting |
title_full | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting |
title_fullStr | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting |
title_full_unstemmed | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting |
title_short | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting |
title_sort | modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high hiv-prevalence setting |
topic | Basic Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150186/ https://www.ncbi.nlm.nih.gov/pubmed/30096067 http://dx.doi.org/10.1097/QAD.0000000000001959 |
work_keys_str_mv | AT rhinesallisons modelingtheimplementationofpopulationlevelisoniazidpreventivetherapyfortuberculosiscontrolinahighhivprevalencesetting AT feldmanmarcusw modelingtheimplementationofpopulationlevelisoniazidpreventivetherapyfortuberculosiscontrolinahighhivprevalencesetting AT bendavideran modelingtheimplementationofpopulationlevelisoniazidpreventivetherapyfortuberculosiscontrolinahighhivprevalencesetting |